Provided by Tiger Trade Technology Pte. Ltd.

ACADIA Pharmaceuticals

28.93
+0.04000.14%
Post-market: 28.930.00000.00%19:30 EDT
Volume:1.56M
Turnover:45.24M
Market Cap:4.98B
PE:13.18
High:29.75
Open:29.10
Low:28.88
Close:28.89
52wk High:30.96
52wk Low:19.69
Shares:172.31M
Float Shares:128.72M
Volume Ratio:1.39
T/O Rate:1.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.20
EPS(LYR):2.30
ROE:35.74%
ROA:3.64%
PB:3.82
PE(LYR):12.58

Loading ...

Acadia Pharmaceuticals' Remlifanserin Shows Favorable Setup Ahead of Phase 2 Data, RBC Says

MT Newswires Live
·
Mar 24

RBC Capital Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Mar 24

ACADIA Pharmaceuticals director Jonathan Poole files initial beneficial ownership statement

Reuters
·
Mar 21

ACADIA Pharmaceuticals appoints Jonathan M. Poole to board and audit committee

Reuters
·
Mar 05

ACADIA Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
Mar 05

U.S. RESEARCH ROUNDUP-CrowdStrike, Oracle, Vulcan Materials

Reuters
·
Mar 04

ACADIA Pharmaceuticals Inc : JP Morgan Raises Target Price to $34 From $31

THOMSON REUTERS
·
Mar 04

ACADIA Pharmaceuticals Appoints Jonathan M. Poole to Board of Directors

Reuters
·
Mar 04

BUZZ-Australia's Neuren Pharmaceuticals drops as US partner seeks EMA re-examination

Reuters
·
Mar 03

European Regulators Recommend Against Acadia's Application for Rett Syndrome Treatment

Dow Jones
·
Mar 03

EMA CHMP Issues Negative Opinion on Acadia Trofinetide for Rett Syndrome

Reuters
·
Mar 03

Stock Track | ACADIA Pharmaceuticals Plummets 7.37% Intraday on Negative CHMP Opinion for Trofinetide

Stock Track
·
Mar 03

ACADIA Pharmaceuticals Announces Plan to Request Re-Examination Following Negative Chmp Opinion for Trofinetide for the Treatment of Rett Syndrome

THOMSON REUTERS
·
Mar 03

ACADIA Pharmaceuticals Charts Growth Path After Record Year

TIPRANKS
·
Mar 02

ACADIA Pharmaceuticals' Rett Syndrome Drug Faces EMA Setback

MT Newswires Live
·
Feb 27

Ema's Chmp: Committee Recommended Not Granting Marketing Authorisation for Daybu (Trofinetide)

THOMSON REUTERS
·
Feb 27

AcadeMedia Expands Share Capital After Warrant Exercise

TIPRANKS
·
Feb 27